Search
Telomir Pharmaceuticals Inc
TELOAdd to Watchlist
1.270USD
-0.030-2.31%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
42.97MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-2.31%
5 Days
+2.42%
1 Month
0.00%
6 Months
-5.22%
Year to Date
-4.51%
1 Year
+10.43%
Key Figures
1.310Open
1.340High
47.05KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
0.14%Turnover Ratio
1.300Prev. Close
1.270Low
45.72KTurnover
LossP/E Static
6.16P/B
0.00%Div Yield TTM
-293.73%ROA
3.10052wk High
1.21Volume Ratio
-16.53MNet Profit
33.83MShares
-0.2846EPS TTM
--Beta
-384.26%ROE
1.05052wk Low
5.38%Amplitude
--Gross Margin
42.97MMarket Cap
0.51Reward/Risk
4.63%Risk Rate
TradingKey Stock Score of Telomir Pharmaceuticals Inc
Currency: USD Updated: 2026-07-02Key Insights
Telomir Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 133 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 15.50.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Telomir Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Telomir Pharmaceuticals Inc Highlights
StrengthsRisks
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
Fairly Valued
The company’s latest PE is -4.46, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 3.42M shares, increasing 12.50% quarter-over-quarter.
Analyst Rating
Based on
0
analysts
--
Current Rating
15.500
Target Price
+1120.47%
Upside Space
Telomir Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Telomir Pharmaceuticals Inc Info
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
Ticker SymbolTELO
CompanyTelomir Pharmaceuticals Inc
CEOAminov (Erez)
Websitehttps://telomirpharma.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Telomir Pharmaceuticals Inc (TELO)?
The current price of Telomir Pharmaceuticals Inc (TELO) is 1.27.
What is the symbol of Telomir Pharmaceuticals Inc?
The ticker symbol of Telomir Pharmaceuticals Inc is TELO.
What is the 52-week high of Telomir Pharmaceuticals Inc?
The 52-week high of Telomir Pharmaceuticals Inc is 3.10.
What is the 52-week low of Telomir Pharmaceuticals Inc?
The 52-week low of Telomir Pharmaceuticals Inc is 1.05.
What is the market capitalization of Telomir Pharmaceuticals Inc?
The market capitalization of Telomir Pharmaceuticals Inc is 42.97M.
What is the Earnings Per Share (EPS TTM) of Telomir Pharmaceuticals Inc (TELO)?
The Earnings Per Share (EPS TTM) of Telomir Pharmaceuticals Inc (TELO) is -0.33.